Emerging data suggest Retatru tide , a dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , may offer a notable step forward for body treatment. Preliminary human tests have shown substantial losses in visceral mass , conceivably exceeding existing obesity therapies . Nevertheless , more study is needed to complet